CHINA PHARMA HOLDINGS, INC.
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Dean PhillipsHouse · D · MN |
CPHICHINA PHARMA HOLDINGS, INC. · Stock |
Sale $15,001 - $50,000 |
Aug 13, 2021 | Jul 1, 2021 | Filing ↗ |
Whale Activity
- Increased2
- New6
- Held1
- Decreased0
- Closed5
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 308.4K | $203K | new |
| JANE STREET GROUP, LLC | 35.5K | $23K | increased |
| Virtu Financial LLC | 24.1K | $16K | new |
| StoneX Group Inc. | 16.3K | $14K | new |
| XTX Topco Ltd | 12.5K | $8K | new |
| UBS Group AG | 7,465 | $5K | increased |
| CITIGROUP INC | 4,314 | $3K | new |
| Caitong International Asset Management Co., Ltd | 1 | $1 | new |
| DANSKE BANK A/S | 1 | $1 | held |
| EFG International AG | 0 | $0 | closed |
| Ground Swell Capital, LLC | 0 | $0 | closed |
| TWO SIGMA SECURITIES, LLC | 0 | $0 | closed |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Li ZhilinCEO & Interim CFO · Director · 10% owner | Grant / award | +13.8M | $0.14 | $1.9M | Sep 29, 2023 | Form 4 ↗ |
| Li ZhilinCEO & Interim CFO · Director · 10% owner | Grant / award | +1.8M | $0.67 | $1.2M | Sep 9, 2021 | Form 4 ↗ |
| Li ZhilinCEO and interim CFO · Director · 10% owner | Grant / award | +2.0M | $0.00 | $0 | Dec 23, 2020 | Form 4 ↗ |
| WAUNG FRANKChief Financial Officer | Grant / award | +100.0K | $0.00 | $0 | Apr 28, 2012 | Form 4 ↗ |
| WAUNG FRANKChief Financial Officer | Grant / award | +100.0K | $0.00 | $0 | Apr 28, 2012 | Form 4 ↗ |
| Li ZhilinPresident and CEO · Director · 10% owner | Grant / award | +50.0K | $0.00 | $0 | May 25, 2011 | Form 4 ↗ |
| WAUNG FRANKChief Financial Officer | Grant / award | +25.0K | $0.00 | $0 | May 25, 2011 | Form 4 ↗ |
| WAUNG FRANKChief Financial Officer | Grant / award | +6,863 | $0.00 | $0 | Dec 13, 2010 | Form 4 ↗ |
| WAUNG FRANKChief Financial Officer | Option exercise | +4,052 | — | — | Nov 15, 2010 | Form 4 ↗ |
Fund Holders
No mutual fund or ETF has reported CPHI in an N-PORT filing in the last seven months.
Activist & Passive Stakes
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
No lobbying filings found naming CHINA PHARMA HOLDINGS, INC. as the client.
Government Contracts
No federal contract awards found for CHINA PHARMA HOLDINGS, INC..
U.S. Patents
No USPTO patent applications found for CHINA PHARMA HOLDINGS, INC..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M |
| Operating income | -$3.2M | -$4.6M | -$2.8M | -$3.5M | -$2.9M |
| Net income | -$3.2M | -$4.7M | -$3.1M | -$4.0M | -$3.4M |
| Diluted EPS | -$0.74 | -$2.71 | -$0.91 | -$3.78 | -$0.74 |
| Operating cash flow | $148K | -$406K | -$700K | -$410K | -$250K |
| Cash and equivalents | $345K | $627K | $1.4M | $2.0M | $4.9M |
| Total assets | $31.0M | $14.9M | $16.5M | $17.8M | $22.6M |
| Total liabilities | $8.3M | $7.1M | $9.0M | $13.5M | $16.6M |
| Shareholders' equity | $22.7M | $7.7M | $7.5M | $4.3M | $6.0M |
As CHINA PHARMA HOLDINGS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Apr 1, 2026 ↗
Stock Splits
- 1-for-10Reverse splitApr 15, 2025
- 1-for-5Reverse splitMar 6, 2024
- 1-for-10Reverse splitMar 6, 2023
- 1-for-20Reverse splitAug 15, 2003
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
- 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsJul 22, 2026
EDGAR ↗

